NASDAQ:EGRX

Eagle Pharmaceuticals Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy EGRX

*Your capital is at risk

$0.460

+0 (+0%)

At Close: Jun 03, 2026

Eagle Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 1.27M and sold 271.88K EGRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	1.27M shares
● Sell	271.88K shares
46% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 11, 2024 Buy	Common Stock J-Other	Krawtschuk Christopher Insider	Other	0 Value: $0
Nov 11, 2024 Buy	Common Stock J-Other	Krawtschuk Christopher Insider	Other	0 Value: $0
Feb 28, 2024 Sell	Common Stock F-InKind	Tarriff Scott 10 Percent Owner	10% Owner	2 119 Value: $13.3K
Feb 28, 2024 Sell	Common Stock F-InKind	Tarriff Scott 10 Percent Owner	10% Owner	2 119 Value: $13.3K
Feb 27, 2024 Buy	Common Stock A-Award	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	3 800 Value: $0
Feb 27, 2024 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	1 589 Value: $10.2K
Feb 27, 2024 Buy	Common Stock A-Award	Tarriff Scott 10 Percent Owner	10% Owner	12 950 Value: $0
Feb 27, 2024 Sell	Common Stock F-InKind	Tarriff Scott 10 Percent Owner	10% Owner	3 154 Value: $20.3K
Feb 27, 2024 Sell	Common Stock F-InKind	Tarriff Scott 10 Percent Owner	10% Owner	3 154 Value: $20.3K
Feb 27, 2024 Buy	Common Stock A-Award	Tarriff Scott 10 Percent Owner	10% Owner	12 950 Value: $0
Feb 27, 2024 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	1 589 Value: $10.2K
Feb 27, 2024 Buy	Common Stock A-Award	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	3 800 Value: $0
Feb 02, 2024 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	934 Value: $5K
Feb 02, 2024 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	934 Value: $5K
Jan 05, 2024 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	735 Value: $4K
Jan 05, 2024 Sell	Common Stock F-InKind	Tarriff Scott 10 Percent Owner	10% Owner	4 322 Value: $22.2K
Jan 05, 2024 Sell	Common Stock F-InKind	Tarriff Scott 10 Percent Owner	10% Owner	4 322 Value: $22.2K
Jan 05, 2024 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	735 Value: $4K
Dec 21, 2023 Buy	Employee Stock Option (right to buy) A-Award	Graves Michael Interim Executive Chair & Peo	Officer	293 000 Value: $1.47M
Dec 21, 2023 Buy	Employee Stock Option (right to buy) A-Award	Graves Michael Interim Executive Chair & Peo	Officer	293 000 Value: $1.47M
Dec 18, 2023 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	452 Value: $2K
Dec 18, 2023 Sell	Common Stock F-InKind	Cahill Brian Joseph Chief Financial Officer	C-Suite Officer	452 Value: $2K
Nov 02, 2023 Sell	Common Stock S-Sale	Tarriff Scott CEO	CEO / President	10 694 Value: $148.3K
Nov 02, 2023 Sell	Common Stock S-Sale	Tarriff Scott CEO	CEO / President	10 694 Value: $148.3K
Nov 01, 2023 Sell	Common Stock S-Sale	Tarriff Scott CEO	CEO / President	10 925 Value: $151.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EAGLE PHARMACEUTICALS

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium ...

Read Full Profile Here